# Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients

> **NCT06406153** · PHASE3 · COMPLETED · sponsor: **Cinnagen** · enrollment: 12 (actual)

## Conditions studied

- Mucopolysaccharidosis Type 1

## Interventions

- **BIOLOGICAL:** Laronidase
- **DRUG:** Antihistamine
- **DRUG:** Antipyretic

## Key facts

- **NCT ID:** NCT06406153
- **Lead sponsor:** Cinnagen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-10
- **Primary completion:** 2023-08-12
- **Final completion:** 2023-11-18
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2024-08-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06406153

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06406153, "Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT06406153. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*